Literature DB >> 25306166

Robotic-assisted sacrocolpopexy for pelvic organ prolapse.

Wesley M White1, Ryan B Pickens2, Robert F Elder3, Farzeen Firoozi4.   

Abstract

The demand for surgical correction of pelvic organ prolapse is expected to grow as the aging population remains active and focused on quality of life. Definitive correction of pelvic organ prolapse can be accomplished through both vaginal and abdominal approaches. This article provides a contemporary reference source that specifically addresses the historical framework, diagnostic algorithm, and therapeutic options for the treatment of female pelvic organ prolapse. Particular emphasis is placed on the role and technique of abdominal-based reconstruction using robotic technology and the evolving controversy regarding the use of synthetic vaginal mesh.
Copyright © 2014 Elsevier Inc. All rights reserved.

Keywords:  Incontinence; Laparoscopy; Outcomes; Pelvic organ prolapse; Robotics

Mesh:

Year:  2014        PMID: 25306166     DOI: 10.1016/j.ucl.2014.07.009

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  4 in total

1.  Successful Pregnancy Outcome After Laparoscopic Sacrohysteropexy for Pelvic Organ Prolapse.

Authors:  Subha R Samantray; Ipsita Mohapatra
Journal:  Cureus       Date:  2021-02-02

2.  Pregnancy and Vaginal Delivery after Sacrohysteropexy.

Authors:  Deniz Balsak; Ahmet Eser; Onur Erol; Derya Deniz Altıntaş; Şerif Aksin
Journal:  Case Rep Obstet Gynecol       Date:  2015-06-23

Review 3.  Laparoscopic versus robotic-assisted sacrocolpopexy for pelvic organ prolapse: a systematic review.

Authors:  Geertje Callewaert; Jan Bosteels; Susanne Housmans; Jasper Verguts; Ben Van Cleynenbreugel; Frank Van der Aa; Dirk De Ridder; Ignace Vergote; Jan Deprest
Journal:  Gynecol Surg       Date:  2016-01-26

Review 4.  Update on the Pathophysiology and Management of Anorectal Disorders.

Authors:  Tanisa Patcharatrakul; Satish S C Rao
Journal:  Gut Liver       Date:  2018-07-15       Impact factor: 4.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.